CME Presentations

Bladder Cancer


Presentations


Speakers

  • Noah M. Hahn, MD

    Noah M. Hahn, MD

    Noah M. Hahn, MD

    Associate Professor of Medicine, Department of Oncology and Urology; Director, Medical Oncology Bladder Cancer Program

    Noah M. Hahn, MD, is an associate professor of oncology and urology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, and is director of the Medical Oncology Bladder Cancer Program and deputy director of the Johns Hopkins Greenberg Bladder Cancer Institute. Dr Hahn is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations. He serves as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network.
  • Matthew Galsky, MD

    Matthew Galsky, MD

    Matthew Galsky, MD

    Director of Genitourinary Medical Oncology

    Matthew Galsky, MD, is the director of genitourinary medical oncology at the Mount Sinai School of Medicine Tisch Cancer Institute in New York. Dr Galsky specializes in caring for patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the clinical development of novel therapies for genitourinary cancers, with a particular emphasis on bladder cancer, and he regularly speaks nationally and internationally on the topic. His research has been published in numerous journals, including the Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology and Lancet, and has been funded by organizations that include the National Institutes of Health/National Cancer Institute and the Department of Defense.

CME Information

Immunotherapy for Bladder Cancer: Implementing Effective Urology Practices


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Appraise the latest data and clinical practice guidelines on the integration of immune checkpoint inhibitors into first- and second-line treatment of advanced bladder cancer
  • Select immunotherapy for advanced bladder cancer based on updated indications for biomarker testing
  • Manage toxicities associated with immunotherapy in patients with advanced bladder cancer
  • Apply principles of shared decision-making to reach treatment decisions in collaboration with patients who have advanced bladder cancer

ACKNOWLEDGEMENT

This activity is supported by an educational grant from AstraZeneca

TUITION

Complimentary

Jointly Accredited Provider Logo





JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

CREDIT DESIGNATION STATEMENTS

Live Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Internet Activity
Wednesday, September 18, 2019 from 12:00 PM EDT – 1:00 PM EDT.

Enduring Material
The enduring material will be available from September 18, 2019 to March 18, 2020.

TARGET AUDIENCE

This activity is intended for genitourinary and medical oncologists, urologists, oncology advanced practice providers, oncology nurses, internists, primary care physicians, and other clinicians interested/involved in the management of patients with bladder cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Noah M. Hahn, MD
Associate Professor of Medicine, Department of Oncology and Urology
Director, Medical Oncology Bladder Cancer Program
Johns Hopkins University School of Medicine
Consulting Fees: BMS, Champions Oncology, CiclloMed, Ferring, Genentech, Health Advances, Incyte, Inovio, Janssen, Merck, Principia Bio pharma, Rexahn, Seattle Genetics, TARIS Bio Medical, Trans Med
Contracted Research: Astex, AstraZeneca, BMS, Genentech, Incyte, Merck, Principia Biopharma, Pieris, Seattle Genetics
Other Honoraria: Bladder Cancer Academy, PierView
Matthew D. Galsky, MD Professor of Medicine, Director, Genitourinary Medical Oncology Icahn School of Medicine at Mount Sinai Consulting Fees: AstraZeneca, BMS, Dragonfly, Genentech, Merck, Numab, Seattle Genetics Contracted Research: AstraZeneca, BMS, Genentech, Merck

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Agnes Lee Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For issues with your CME Certificate, please contact UroCareLive at 877-394-1306 or at Support@UroCareLive.com or OMedLive at 877-394-1306 or at Support@OMedLive.com.